However, approximately 510% of patients discontinue treatment due to persistent gastrointestinal intolerance
Along with the heterogeneity of the disease and the lack of reliable biomarkers, the problem for developing specific treatments for PD is its multiple pathophysiological mechanisms, many of which are common to the mechanisms of T2DM development, including brain insulin resistance, impaired energy and glucose metabolism, mitochondrial dysfunction, chronic systemic inflammation, neuroinflammation, impaired lysosome function, and oxidative stress [56, 57]
Triple-Hormone Action Retatrutide acts on GLP-1, GIP, and glucagon receptors
This real-world dataset offers several unique advantages for studying GLP-1 medications: Timely data: Truveta Data is updated daily, providing near real-time insights critical for tracking prescribing trends, medication shortages, and emerging treatment patterns in a rapidly evolving landscape
The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact
